“showed a trend”

Groups E and ME showed a trend towards increased cardiomyocyte area when compared with group S ( p = 0.13 and p = 0.19, respectively).

In these cases, LFP duration increased from 232 ± 27.7 ms in control to 624 ± 150 ms ( p = 0.002) (i.e., 2.7-fold), whereas the LFP rate showed a trend to rise from 42.3 ± 7.2/min to 57.3 ± 15.6 events/min ( p = 0.13). 3.3.

A concentration of 50 μM showed a trend towards increased LDH release, although the difference to untreated control cells remained statistically non-significant ( p = 0.13).

Males and females demonstrated similar urinary excretion of renal net acid, magnesium and sulfate; males showed a trend for higher urinary calcium excretion compared to females (means ± SE, males: 339 ± 75 mg/d, females: 228 ± 69 mg/d; p = 0.13).

In the LUAD-like group, continuing EGFR-TKI treatment showed a trend towards longer PFS compared to discontinuation (6.2 months (95%CI, 4.4–8.0 months) vs. 3.6 months (95%CI, 1.2–6.1 months), p = 0.13).

While diabetes mellitus showed a trend toward association with HFpEF in univariate analysis (OR 1.33, 95% CI 0.92–1.92, P = 0.13), it did not reach statistical significance for inclusion in our final model. 3.3.

Blood CD4 + T cell levels showed a trend toward CD4 restoration ( r = 0.24; P = 0.13) with only a 1.3-fold reduction ( P = 0.2) in participants receiving ART for more than 10 years ( Figure 4D ), and this is consistent with a 1.1 reduction in absolute CD4 + T cell counts (HIV – versus HIV + VL < 20 ART > 10 years, median 858 versus 795 cells/mm 3 , P = 0.99).

Further, the decorin microrod group showed a trend in improved arteriole density compared to the vehicle group in the remote zone (Fig. 6d , Supplementary Table 9 ; p = 0.13).

Patients with no detectable ctDNA at any time point postoperatively showed a trend toward improved RFS (RFS = 85%) compared with those with detectable ctDNA (58%), with an HR of 0.34 (95% CI, 0.13–0.92; P = 0.130).

From bulk RNA-seq of PDAC samples, TRIM22 showed a trend of being upregulated ( P = 0.13 ), whereas HIST1H3B was significantly downregulated ( P = 0.0009 ) in ulixertinib-treated cohorts (Supplementary Fig.

However, brachial DBP reduction did not reach statistical significance but showed a trend toward decrease (−5.10 mmHg [95% CI: −11.71 to 1.52], p = 0.13).

Patients with elevated cfDNA (≥3.35 log 10 hGE/ml, as defined by a Cox regression model) showed a trend towards inferior PFS ( p = 0.13, HR = 3.1, 95% Cl=0.64–14.95) (Fig. 3E ).

The Six2DE showed a trend of greater accessibility in low CHIR versus high CHIR condition (peak ID 10164, adjusted p-value=0.13).

Although the high APOC2 expression group showed a trend toward lower survival compared to the low expression group, this difference was not statistically significant (log-rank test, p = 0.13) ( Figure 4 B).

Excluding the 8 infants who were studied at both time points, HEU infants showed a trend toward higher NK cell proportions at 6 months compared to birth (increase from median of 1.85% at birth to 3.12% at 6 months; p = 0.13), whereas HUU infants had lower NK cell proportions at 6 months compared to birth (decrease from 9.4% at birth to 4.65% at 6 months; p < 0.0001).

In our model, TGFβ inhibition reduced early intracranial tumor burden, and survival showed a trend toward prolongation (MST 15 vs. 14 days; P = 0.13, log-rank).

Earlier closure of gastroschisis correlated with early initiation of feeds (p=0.0001) and shorter time to full feeds (p=0.018), closure by DOL4 showed a trend toward earlier feeding (p=0.13).

This cohort showed a trend toward longer median PFS (not reached vs. 15.8 months; both p = 0.13) and a higher 2-year overall survival rate (100% vs. 92.6%; p = 0.46) than those who did not receive surgery (Supplementary Fig.

Patients <55 also showed a trend towards an increased risk of death with a HR of 1.49 (p=0.13).

Picolinic acid addition showed a trend (p = 0.13) toward increased lifespan.

4%, HR 8.9, 95% CI 3.0–26.0, P < 0.01), whereas patients with EuroSCORE II scores above the 75 th percentile (> 6.8) only showed a trend towards higher mortality (18% vs. 9%, HR 2.1, 95% CI 0.8–5.6, P = 0.13).

p16-L16R patients without cancer (20% growth per day) showed a trend ( p = 0.13 in two-tailed t -tests) toward higher growth rates than WT cells, supporting the idea that p16-L16R increases growth rates, even in subjects without cancer.

Interestingly, whereas the forelimb impact impulses showed a trend for negative allometry (M b 0.99±0.11 , p = 0.13; M b 1.05±0.22 , p = 0.59, walk and slow run respectively), the hind limb impact impulses showed a trend for positive allometry (M b 1.38±0.14 , p = 0.15; M b 1.21±0.22 , p = 0.86 walk and slow run respectively).

Further, both the stroke groups showed a trend of shorter compensatory steps than healthy older adults ( p = 0.13).

The pooled results showed a trend favoring the HA group, but did not show any differences (MD 6.01; 95%CI −1.74 to 13.75; P = 0.13).